170 related articles for article (PubMed ID: 38142463)
1. FBXW7 regulates the sensitivity of imatinib in gastrointestinal stromal tumors by targeting MCL1.
Wu X; Iwatsuki M; Takaki M; Saito T; Hayashi T; Kondo M; Sakai Y; Gotohda N; Tanaka E; Nishida T; Baba H
Gastric Cancer; 2024 Mar; 27(2):235-247. PubMed ID: 38142463
[TBL] [Abstract][Full Text] [Related]
2. The role of FBXW7, a cell-cycle regulator, as a predictive marker of recurrence of gastrointestinal stromal tumors.
Koga Y; Iwatsuki M; Yamashita K; Kiyozumi Y; Kurashige J; Masuda T; Eto K; Iwagami S; Harada K; Ishimoto T; Baba Y; Yoshida N; Miyanari N; Takamori H; Ajani JA; Baba H
Gastric Cancer; 2019 Nov; 22(6):1100-1108. PubMed ID: 30854619
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Long-Term Adjuvant Therapy With Imatinib Mesylate After Extensive Surgical Treatment for Ruptured Gastrointestinal Stromal Tumors of the Small Intestine With Peritoneal Metastases: A Case Report.
Kimura T; Togawa T; Onishi K; Iida A; Sato Y; Goi T
J Investig Med High Impact Case Rep; 2020; 8():2324709620970736. PubMed ID: 33228387
[TBL] [Abstract][Full Text] [Related]
4. Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.
Gasca J; Flores ML; Giráldez S; Ruiz-Borrego M; Tortolero M; Romero F; Japón MA; Sáez C
Oncotarget; 2016 Aug; 7(33):52751-52765. PubMed ID: 27409838
[TBL] [Abstract][Full Text] [Related]
5. SPK1/S1P axis confers gastrointestinal stromal tumors (GISTs) resistance of imatinib.
Chen Y; Zhang R; Mi D; Wang Q; Huang T; Dong X; Zhang H; Xiao H; Shi S
Gastric Cancer; 2023 Jan; 26(1):26-43. PubMed ID: 35999321
[TBL] [Abstract][Full Text] [Related]
6. Postoperative imatinib in patients with intermediate risk gastrointestinal stromal tumor.
Wu X; Li J; Xu W; Gao J; Li Y; Shen L
Future Oncol; 2018 Jul; 14(17):1721-1729. PubMed ID: 29969914
[TBL] [Abstract][Full Text] [Related]
7. BRD9 inhibition promotes PUMA-dependent apoptosis and augments the effect of imatinib in gastrointestinal stromal tumors.
Mu J; Sun X; Zhao Z; Sun H; Sun P
Cell Death Dis; 2021 Oct; 12(11):962. PubMed ID: 34667163
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome.
Zhao WY; Xu J; Wang M; Zhang ZZ; Tu L; Wang CJ; Cao H; Zhang ZG
BMC Gastroenterol; 2014 Jun; 14():105. PubMed ID: 24906683
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
Raut CP; Espat NJ; Maki RG; Araujo DM; Trent J; Williams TF; Purkayastha DD; DeMatteo RP
JAMA Oncol; 2018 Dec; 4(12):e184060. PubMed ID: 30383140
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.
Fu Y; Hao H; Guo L; Yang G; Zhang X
Oncotarget; 2017 Feb; 8(6):10136-10144. PubMed ID: 28052037
[TBL] [Abstract][Full Text] [Related]
11. Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment.
Ihle MA; Huss S; Jeske W; Hartmann W; Merkelbach-Bruse S; Schildhaus HU; Büttner R; Sihto H; Sundby Hall K; Eriksson M; Reichardt P; Joensuu H; Wardelmann E
PLoS One; 2018; 13(2):e0193048. PubMed ID: 29451912
[TBL] [Abstract][Full Text] [Related]
12. Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome.
Cavnar MJ; Wang L; Balachandran VP; Antonescu CR; Tap WD; Keohan M; Singer S; Temple L; Nash GM; Weiser MR; Guillem JG; Aguilar JG; DeMatteo RP; Paty PB
Ann Surg Oncol; 2017 Dec; 24(13):3972-3980. PubMed ID: 29058144
[TBL] [Abstract][Full Text] [Related]
13. Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours.
Naito Y; Nishida T; Doi T
Gastric Cancer; 2023 May; 26(3):339-351. PubMed ID: 36913072
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
15. PIK3C2A is a gene-specific target of microRNA-518a-5p in imatinib mesylate-resistant gastrointestinal stromal tumor.
Shi Y; Gao X; Hu Q; Li X; Xu J; Lu S; Liu Y; Xu C; Jiang D; Lin J; Xue A; Tan Y; Shen K; Hou Y
Lab Invest; 2016 Jun; 96(6):652-60. PubMed ID: 26950487
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib.
Serrano C; García-Del-Muro X; Valverde C; Sebio A; Durán J; Manzano A; Pajares I; Hindi N; Landolfi S; Jiménez L; Rubió-Casadevall J; Estival A; Lavernia J; Safont MJ; Pericay C; Díaz-Beveridge R; Martínez-Marín V; Vicente-Baz D; Vivancos A; Hernández-Losa J; Arribas J; Carles J
Oncologist; 2019 May; 24(5):680-687. PubMed ID: 30126859
[TBL] [Abstract][Full Text] [Related]
17. Imatinib Regulates
Huang WK; Shi H; Akçakaya P; Zeljic K; Gangaev A; Caramuta S; Yeh CN; Bränström R; Larsson C; Lui WO
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638938
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of stromal-interacting molecule 1-mediated store-operated Ca
Yang Z; Pan L; Liu S; Li F; Lv W; Shu Y; Dong P
Cancer Sci; 2018 Sep; 109(9):2792-2800. PubMed ID: 29957833
[TBL] [Abstract][Full Text] [Related]
19. KIT and BRAF heterogeneous mutations in gastrointestinal stromal tumors after secondary imatinib resistance.
Zheng S; Huang KE; Pan YL; Zhou Y; Pan SD; Li X; Jia J; Zheng XL; Tao DY
Gastric Cancer; 2015 Oct; 18(4):796-802. PubMed ID: 25182956
[TBL] [Abstract][Full Text] [Related]
20. The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors.
Keung EZ; Fairweather M; Raut CP
Curr Treat Options Oncol; 2016 Feb; 17(2):8. PubMed ID: 26820287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
